TANDEM DIABETES CARE INC (TNDM) — SEC Financial Statements & Analysis

TANDEM DIABETES CARE INC (TNDM) is a surgical & medical instruments & apparatus company, incorporated in DE. TANDEM DIABETES CARE INC trades on Nasdaq as: TNDM. TANDEM DIABETES CARE INC (TNDM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, TANDEM DIABETES CARE INC carries a market cap of $1.04B, a P/E ratio of -16.45x, a P/B ratio of 7.99x, a P/S ratio of 1.00x, an enterprise value of $1.58B, and an EV/EBITDA multiple of -56.81x. On profitability, it posts a gross margin of 56.01%, an operating margin of -4.40%, a net margin of -6.08%, a Return on Equity (ROE) of -48.03%, a Return on Assets (ROA) of -6.24%, and a Return on Invested Capital (ROIC) of -8.41%. Per share, it reports EPS of $-0.92, diluted EPS of $-0.92, free cash flow per share of $-0.39, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 3.96% year-over-year, net income growth of -69.18% year-over-year, and EPS growth of -70.06% year-over-year. On the balance sheet, it maintains a current ratio of 3.18x, a quick ratio of 2.44x, working capital of $551.63M, a debt-to-equity ratio of 7.85x, a debt ratio of 0.89, an interest coverage ratio of -5.21x, free cash flow of $-26.62M (TTM), and net debt of $539.76M. Figures sourced from SEC EDGAR.

Market Cap

$1.04B

P/E TTM

-16.45x

EPS TTM

$-0.92

P/B TTM

7.99x

ROE TTM

-48.03%

ROA TTM

-6.24%

Debt To Equity

7.85x

Free Cash Flow TTM

$-26.62M

Net Revenue TTM Growth 1Y

3.96%

Data as of 2026-06-30 · Source: SEC EDGAR